Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov;54(11):e2250336.
doi: 10.1002/eji.202250336. Epub 2024 Aug 27.

Expanding our understanding of Guillain-Barré syndrome: Recent advances and clinical implications

Affiliations
Free article
Review

Expanding our understanding of Guillain-Barré syndrome: Recent advances and clinical implications

Paolo Ripellino et al. Eur J Immunol. 2024 Nov.
Free article

Abstract

Guillain-Barré syndrome (GBS) is a rare yet potentially life-threatening disorder of the peripheral nervous system (PNS), characterized by substantial clinical heterogeneity. Although classified as an autoimmune disease, the immune mechanisms underpinning distinct GBS subtypes remain largely elusive. Traditionally considered primarily antibody-mediated, the pathophysiology of GBS lacks clarity, posing challenges in the development of targeted and effective treatments. Nevertheless, recent investigations have substantially expanded our understanding of the disease, revealing an involvement of autoreactive T cell immunity in a major subtype of GBS patients and opening new biomedical perspectives. This review highlights these discoveries and offers a comprehensive overview of current knowledge about GBS, including ongoing challenges in disease management.

Keywords: Acute inflammatory demyelinating polyradiculoneuropathy (AIDP); Autoimmunity; Autoreactive T cells; Guillain–Barré syndrome; Immunopathology.

PubMed Disclaimer

References

    1. Shahrizaila, N., Lehmann, H. C. and Kuwabara, S., Guillain‐Barre syndrome. Lancet. 2021. 397: 1214–1228.
    1. Willison, H. J., Jacobs, B. C. and van Doorn, P. A., Guillain‐Barre syndrome. Lancet. 2016. 388: 717–727.
    1. Van den Bergh, P. Y. K., van Doorn, P. A., Hadden, R. D. M., Avau, B., Vankrunkelsven, P., Allen, J. A., Attarian, S. et al., European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force‐second revision. J. Peripher. Nerv. Syst. 2021. 26: 242–268.
    1. Sejvar, J. J., Baughman, A. L., Wise, M. and Morgan, O. W., Population incidence of Guillain‐Barre syndrome: a systematic review and meta‐analysis. Neuroepidemiology. 2011. 36: 123–133.
    1. Webb, A. J., Brain, S. A., Wood, R., Rinaldi, S. and Turner, M. R., Seasonal variation in Guillain‐Barre syndrome: a systematic review, meta‐analysis and Oxfordshire cohort study. J. Neurol. Neurosurg. Psychiatry. 2015. 86: 1196–1201.

LinkOut - more resources